COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BELGIUM: ANALYSIS USING 48-MONTH OVERALL SURVIVAL FROM CHECKMATE 067

被引：0
|
作者：
Baker, T. [1 ]
Paly, V. F. [1 ]
Johnson, H. M. [2 ]
Van Campenhout, H. [3 ]
Amadi, A. [2 ]
Chandran, N. [4 ]
Moshyk, A. [5 ]
Kotapati, S. [5 ]
机构：
[1] ICON Plc, New York, NY USA
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Braine Lalleud, Belgium
[4] ICON Plc, Bangalore, Karnataka, India
[5] Bristol Myers Squibb, Lawrenceville, NJ USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN142
引用
收藏
页码：S462 / S463
页数：2
相关论文
共 50 条
  • [41] Cost-Effectiveness of Nivolumab-lpilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States
    Oh, Anna
    Tran, Dang M.
    McDowell, Leann C.
    Keyvani, Dor
    Barcelon, Jay Andrew
    Merino, Oscar
    Wilson, Leslie
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (06): : 653 - 664
  • [42] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [43] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [44] First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma A Cost-effectiveness Analysis
    Wan, XiaoMin
    Zhang, YuCong
    Tan, ChongQing
    Zeng, XiaoHui
    Peng, LiuBao
    JAMA ONCOLOGY, 2019, 5 (04) : 491 - 496
  • [45] ECONOMIC EVALUATION OF NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) COMBINATION AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED MELANOMA IN CANADA
    Quon, P.
    Xiao, Y.
    Sorensen, S.
    Schultz, M.
    Monfared, Tahami A. A.
    VALUE IN HEALTH, 2017, 20 (09) : A441 - A442
  • [46] Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line (1L) Treatment (tx) of Advanced Nsclc: Overall Survival (Os) Analysis of Checkmate 817
    Fischer, Juergen R.
    Barlesi, Fabrice
    Audigier-Valette, Larisse
    Felip, Enriqueta
    Ciuleanu, Tudor-Eliade
    Jao, Kevin
    Rijavec, Erika
    Urban, Laszlo
    Aucoin, Jean-Sebastien
    Zannori, Cristina
    Vermaelen, Karim
    Aren Frontera, Osvaldo
    Ready, Neal
    Fontecedro, Alessandra Curioni
    Linardou, Helena
    Poddubskaya, Elena
    Pillai, Rathi
    Li, Sunney
    Acevedo, Angelic
    Paz-Ares, Luis
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 236 - 236
  • [47] A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia
    Bohensky, Megan A.
    Pasupathi, Kumar
    Gorelik, Alexandra
    Kim, Hansoo
    Harrison, James P.
    Liew, Danny
    VALUE IN HEALTH, 2016, 19 (08) : 1009 - 1015
  • [48] COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLAND
    Oniangue-Ndza, C.
    Schneider, R.
    Malcolm, B.
    May, J.
    Gooden, K. M.
    Klijn, S.
    Cakar, E.
    VALUE IN HEALTH, 2019, 22 : S462 - S462
  • [49] COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN ITALY
    Di Rienzo, P.
    Zarrelli, L.
    Mennini, F. S.
    Marcellusi, A.
    Bini, C.
    Malcolm, B.
    May, J.
    Gooden, K. M.
    Van de Wetering, G.
    van Carroll, Smith L. E.
    VALUE IN HEALTH, 2019, 22 : S469 - S469
  • [50] Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
    Cakar, Esra
    Oniangue-Ndza, Cesar
    Schneider, Ralph P. P.
    Klijn, Sven L. L.
    Vogl, Ursula M. M.
    Rothermundt, Christian
    May, Jessica R. R.
    PHARMACOECONOMICS-OPEN, 2023, 7 (04) : 567 - 577
12345